ClexBio is a regenerative medicine company developing novel tissue-engineered solutions to treat various clinical conditions. The first product in the company’s pipeline is a human acellular vein graft to restore valve function and permanently treat venous reflux for patients suffering from chronic venous insufficiency (CVI). The Company’s long-term goal is to create a portfolio of engineered tissues for clinical use, ranging from acellular vein grafts, venous/arterial/neural conduits, to vascularised skin, bone, and other tissues for use in regenerative and reconstructive medicine. The Company's proprietary biomaterial and tissue-engineering core technologies may also be used to create R&D tools for life science applications and, improve current in vitro models for drug testing and diagnostics.